To the Editor In their analysis for limited-stage small cell lung cancer, Pezzi et al1 report that substantial numbers of patients are not receiving standard-of-care treatment. Notably, Medicare/Medicaid beneficiaries were less likely to receive radiotherapy vs the privately insured. The authors theorize that similar effects by insurance status were not observed for chemotherapy partially due to competitive chemotherapy reimbursement afforded by the 340b Drug Pricing Program.
Alcorn SR, Miller DB, Hales RK. Underutilization of Combined-Modality Therapy in Limited-Stage Small Cell Lung Cancer. JAMA Oncol. 2018;4(10):1435–1436. doi:10.1001/jamaoncol.2018.3261
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: